Literature DB >> 32153096

Liver enzyme variability and risk of heart disease and mortality: A nationwide population-based study.

Eun Ju Cho1, Kyungdo Han2, Seung-Pyo Lee3,4, Dong Wook Shin5,6, Su Jong Yu1.   

Abstract

BACKGROUND & AIMS: Liver enzymes, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (GGT), have been suggested as surrogate markers of various cardiovascular diseases. However, previous studies assessed liver enzymes only once at baseline. We investigated the association between liver enzyme variability and the risk of mortality and cardiovascular outcomes in general population.
METHODS: A total of 6 496 271 subjects participating in ≥3 health examinations within the previous 5 years including the index year (2009-2010) were included. Variability was measured using variability independent of the mean. Cox proportional hazard models adjusting demographic factors, comorbidities, blood pressure, total cholesterol, glomerular filtration rate and baseline liver enzyme level were used.
RESULTS: During a median follow-up of 6 years, there were 106 413 deaths (1.6%), 53 385 myocardial infarctions (MI, 0.8%), 65 143 atrial fibrillations (AF, 1.0%) and 50 139 congestive heart failures (CHF, 0.7%). High variability in AST, ALT and GGT was associated with a higher risk for all-cause mortality, MI, AF and CHF. The degree of association was largest for GGT variability. For the highest quartile of GGT variability relative to the lowest quartile, the hazard ratios (95% confidence intervals) were 1.32 (1.28-1.35) for all-cause mortality, 1.16 (1.11-1.20) for MI, 1.28 (1.18-1.38) for AF and 1.25 (1.20-1.30) for CHF. These findings were consistent regardless of alcohol consumption, body mass index and degree of fatty liver. Sensitivity analysis also revealed similar results.
CONCLUSIONS: Higher visit-to-visit variability of liver enzymes was an independent predictor of all-cause mortality and cardiovascular events.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alanine aminotransferase; aspartate aminotransferase; cardiovascular outcome; mortality; variability; γ-glutamyltransferase

Mesh:

Substances:

Year:  2020        PMID: 32153096     DOI: 10.1111/liv.14432

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.

Authors:  Panyavee Pitisuttithum; Wah-Kheong Chan; George Boon-Bee Goh; Jian-Gao Fan; Myeong Jun Song; Phunchai Charatcharoenwitthaya; Ajay Duseja; Yock-Young Dan; Kento Imajo; Atsushi Nakajima; Khek-Yu Ho; Khean-Lee Goh; Vincent Wai-Sun Wong; Sombat Treeprasertsuk
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

2.  Joint Effect of Hepatic Steatosis and Alanine Aminotransferase Within the Normal Range on Incident Ischemic Heart Disease: A Prospective Study in Koreans.

Authors:  Dong-Hyuk Jung; Yong Jae Lee; Byoungjin Park
Journal:  Clin Interv Aging       Date:  2021-03-22       Impact factor: 4.458

3.  Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients.

Authors:  Raika Jamali; Saeed Pourhassan; Nastaran Maghbouli; Haleh Ashraf; Amir Ali Sohrabpour
Journal:  Med J Islam Repub Iran       Date:  2020-10-12

4.  Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults.

Authors:  Jeong-Ju Yoo; Eun Ju Cho; Goh Eun Chung; Young Chang; Yuri Cho; Sang-Hyun Park; Su-Min Jeong; Bo-Yeon Kim; Dong Wook Shin; Yun Joon Kim; Jung-Hwan Yoon; Kyungdo Han; Su Jong Yu
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

5.  Elevated AST/ALT ratio is associated with all-cause mortality and cancer incident.

Authors:  Wangyang Chen; Weibo Wang; Lingling Zhou; Jun Zhou; Lianping He; Jiayi Li; Xinyue Xu; Jixi Wang; Liangyou Wang
Journal:  J Clin Lab Anal       Date:  2022-03-22       Impact factor: 3.124

6.  Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes.

Authors:  Goh-Eun Chung; Kyungdo Han; Kyu-Na Lee; Eun-Ju Cho; Jung-Ho Bae; Sun-Young Yang; Su-Jong Yu; Seung-Ho Choi; Jeong-Yoon Yim; Nam-Ju Heo
Journal:  Biomedicines       Date:  2022-05-26

7.  Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese.

Authors:  Xinyu Wang; Si Cheng; Jun Lv; Canqing Yu; Yu Guo; Pei Pei; Ling Yang; Iona Y Millwood; Robin Walters; Yiping Chen; Huaidong Du; Haiping Duan; Simon Gilbert; Daniel Avery; Junshi Chen; Yuanjie Pang; Zhengming Chen; Liming Li
Journal:  Front Cardiovasc Med       Date:  2022-08-11

8.  The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis.

Authors:  Goh-Eun Chung; Young Chang; Yuri Cho; Eun-Ju Cho; Jeong-Ju Yoo; Sang-Hyun Park; Kyungdo Han; Dong-Wook Shin; Su-Jong Yu; Yoon-Jun Kim; Jung-Hwan Yoon
Journal:  Biomedicines       Date:  2021-12-20

9.  Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study.

Authors:  Kyuhoon Bang; Ji Eun Jun; In-Kyung Jeong; Kyu Jeung Ahn; Ho Yeon Chung; You-Cheol Hwang
Journal:  Diabetes Metab J       Date:  2021-03-17       Impact factor: 5.376

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.